Key result
MyoD1 and myogenin antibodies critically advance rhabdomyosarcoma diagnosis but require careful technical interpretation.
This review highlights the utility and technical considerations of using MyoD1 and myogenin antibodies in the diagnostic pathology of rhabdomyosarcoma.
Supports MyoD1/myogenin IHC in rhabdomyosarcoma workup; leaves open optimal protocol standardization across labs.
The MyoD1 family of myogenic nuclear regulatory proteins includes MyoD1/myf3 and myogenin/myf4. These genes and their proteins are critical for skeletal muscle development. Antibodies to MyoD1 and myogenin are relatively recent additions to the armamentarium of the surgical pathologist. This article reviews the biology of the myogenic nuclear regulatory proteins and their use in the diagnosis of rhabdomyosarcoma. Special attention is given to technical and interpretative issues critical to the use of these antibodies in diagnostic pathology.
No takes yet. Share an insight, caveat, or question.
Andrew L. Folpe (2002) conducted a review in Rhabdomyosarcoma. Antibodies to MyoD1 and myogenin was evaluated. Antibodies to MyoD1 and myogenin are critical additions to diagnostic pathology for rhabdomyosarcoma, requiring special attention to technical and interpretative issues.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: